AAPL   398.20 (+3.78%)
FB   247.19 (+0.87%)
GOOGL   1,560.37 (+1.39%)
NVDA   428.66 (+2.26%)
CGC   18.14 (+4.13%)
BABA   261.18 (+0.07%)
AMD   57.13 (+2.24%)
GILD   77.20 (+1.15%)
DIS   119.77 (+0.36%)
NFLX   564.97 (+2.96%)
BAC   24.07 (+0.21%)
BA   176.53 (-1.07%)
AAPL   398.20 (+3.78%)
FB   247.19 (+0.87%)
GOOGL   1,560.37 (+1.39%)
NVDA   428.66 (+2.26%)
CGC   18.14 (+4.13%)
BABA   261.18 (+0.07%)
AMD   57.13 (+2.24%)
GILD   77.20 (+1.15%)
DIS   119.77 (+0.36%)
NFLX   564.97 (+2.96%)
BAC   24.07 (+0.21%)
BA   176.53 (-1.07%)
AAPL   398.20 (+3.78%)
FB   247.19 (+0.87%)
GOOGL   1,560.37 (+1.39%)
NVDA   428.66 (+2.26%)
CGC   18.14 (+4.13%)
BABA   261.18 (+0.07%)
AMD   57.13 (+2.24%)
GILD   77.20 (+1.15%)
DIS   119.77 (+0.36%)
NFLX   564.97 (+2.96%)
BAC   24.07 (+0.21%)
BA   176.53 (-1.07%)
AAPL   398.20 (+3.78%)
FB   247.19 (+0.87%)
GOOGL   1,560.37 (+1.39%)
NVDA   428.66 (+2.26%)
CGC   18.14 (+4.13%)
BABA   261.18 (+0.07%)
AMD   57.13 (+2.24%)
GILD   77.20 (+1.15%)
DIS   119.77 (+0.36%)
NFLX   564.97 (+2.96%)
BAC   24.07 (+0.21%)
BA   176.53 (-1.07%)
Log in

NASDAQ:CLVSClovis Oncology Stock Price, Forecast & News

$6.56
-0.07 (-1.06 %)
(As of 07/13/2020 10:32 AM ET)
Add
Compare
Today's Range
$6.49
Now: $6.56
$6.67
50-Day Range
$6.48
MA: $6.92
$7.53
52-Week Range
$2.93
Now: $6.56
$17.37
Volume706,026 shs
Average Volume4.04 million shs
Market Capitalization$504.08 million
P/E RatioN/A
Dividend YieldN/A
Beta2.51
Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. As of 4/6/18, Rubraca® (rucaparib) is also approved by the FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. FDA granted regular approval for Rubraca in this second, broader and earlier-line indication on a priority review timeline based on positive data from the phase 3 ARIEL3 clinical trial. Biomarker testing is not required for patients to be prescribed Rubraca in this maintenance treatment indication.
Read More
Clovis Oncology logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.1Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.65 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:CLVS
CUSIP18946410
Phone303-625-5000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$143.01 million
Book Value($3.17) per share

Profitability

Net Income$-400,420,000.00
Net Margins-271.13%

Miscellaneous

EmployeesN/A
Market Cap$504.08 million
Next Earnings Date8/6/2020 (Estimated)
OptionableOptionable

Receive CLVS News and Ratings via Email

Sign-up to receive the latest news and ratings for CLVS and its competitors with MarketBeat's FREE daily newsletter.

Clovis Oncology (NASDAQ:CLVS) Frequently Asked Questions

How has Clovis Oncology's stock been impacted by COVID-19 (Coronavirus)?

Clovis Oncology's stock was trading at $6.17 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CLVS stock has increased by 6.2% and is now trading at $6.55. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Clovis Oncology?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clovis Oncology in the last year. There are currently 2 sell ratings, 5 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Clovis Oncology.

When is Clovis Oncology's next earnings date?

Clovis Oncology is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Clovis Oncology.

How were Clovis Oncology's earnings last quarter?

Clovis Oncology (NASDAQ:CLVS) posted its quarterly earnings results on Tuesday, May, 5th. The biopharmaceutical company reported ($1.28) EPS for the quarter, meeting the consensus estimate of ($1.28). The biopharmaceutical company had revenue of $42.56 million for the quarter, compared to the consensus estimate of $41.80 million. View Clovis Oncology's earnings history.

What price target have analysts set for CLVS?

12 Wall Street analysts have issued twelve-month price targets for Clovis Oncology's shares. Their forecasts range from $4.00 to $36.00. On average, they expect Clovis Oncology's stock price to reach $15.14 in the next twelve months. This suggests a possible upside of 131.2% from the stock's current price. View analysts' price targets for Clovis Oncology.

Has Clovis Oncology been receiving favorable news coverage?

Media headlines about CLVS stock have trended very negative this week, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Clovis Oncology earned a coverage optimism score of -3.2 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news about Clovis Oncology.

Who are some of Clovis Oncology's key competitors?

What other stocks do shareholders of Clovis Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Clovis Oncology investors own include Gilead Sciences (GILD), Micron Technology (MU), Amarin (AMRN), NVIDIA (NVDA), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), Intercept Pharmaceuticals (ICPT), Bristol-Myers Squibb (BMY), Alibaba Group (BABA) and Exelixis (EXEL).

Who are Clovis Oncology's key executives?

Clovis Oncology's management team includes the following people:
  • Mr. Patrick J. Mahaffy MA, Co-Founder, Chief Exec. Officer, Pres and Exec. Director (Age 55)
  • Dr. Gillian C. Ivers-Read BSc, Co-Founder, Chief Regulatory Officer and Exec. VP of Technical Operations (Age 64)
  • Mr. Daniel W. Muehl CPA, Sr. VP of Fin. and Principal Financial & Accounting Officer (Age 54)
  • Dr. Lindsey Rolfe BSc, MB ChB, MRCP, FFPM, Chief Medical Officer and Exec. VP of Clinical, Preclinical Devel. & Pharmacovigilance (Age 50)
  • Mr. Corwin Dale Hooks, Chief Commercial Officer and Sr. VP (Age 51)

What is Clovis Oncology's stock symbol?

Clovis Oncology trades on the NASDAQ under the ticker symbol "CLVS."

How do I buy shares of Clovis Oncology?

Shares of CLVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Clovis Oncology's stock price today?

One share of CLVS stock can currently be purchased for approximately $6.55.

How big of a company is Clovis Oncology?

Clovis Oncology has a market capitalization of $503.70 million and generates $143.01 million in revenue each year. The biopharmaceutical company earns $-400,420,000.00 in net income (profit) each year or ($7.60) on an earnings per share basis.

What is Clovis Oncology's official website?

The official website for Clovis Oncology is www.clovisoncology.com.

How can I contact Clovis Oncology?

Clovis Oncology's mailing address is 5500 FLATIRON PARKWAY SUITE 100, BOULDER CO, 80301. The biopharmaceutical company can be reached via phone at 303-625-5000 or via email at [email protected]

This page was last updated on 7/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.